- MedPlus is India’s second-largest pharmacy retailer, but its real story is a doctor’s mission to kill counterfeit drugs by cutting out the middlemen. Founded in 2006 by Dr Gangadi Madhukar Reddy with 48 stores in Hyderabad, the company has grown into a pan-Indian network of 4,407 neighbourhood outlets by building a technology spine that sources medicines straight from manufacturers and tracks every pill to the patient’s door. Everything MedPlus does flows from one recurring logic: use physical stores as hyperlocal trust anchors, feed them through an integrated supply chain that no standalone chemist can match, and pass the savings on as discounts that pull customers in - then layer private-label products and diagnostics on top of the same footfall.
Business segments
Two engines feed each other - a pharmacy retail network that generates the cash and customer relationships, and a diagnostics business built on the same neighbourhood presence and membership model.
1. Pharmacy retail: the neighbourhood store that doubles as a warehouse
A cluster of 5,330 small-format stores, each acting as a trusted dispensary, a two-hour delivery hub, and a billboard for the company’s own brands - all fed by ten regional warehouses and an in-house technology platform.
- Genuine medicines, direct from the factory - MedPlus sources the majority of its products straight from pharmaceutical manufacturers or authorised wholesalers, bypassing the multi-layered distributor networks where counterfeits enter the supply chain. Suppliers also agree to take back expired or unsold stock, so the company carries almost no perishability risk on branded drugs.
- Two-hour delivery that online-only players cannot copy - because every store sits in a neighbourhood, MedPlus can promise delivery within two hours on online orders, covering both acute and chronic prescriptions. Pure e-pharmacies largely serve only the chronic segment, which is 37% of India’s pharmaceutical market; MedPlus’s physical footprint lets it address the full 100%. The company charges a delivery fee of around ₹20 and offers fast delivery only where customers will pay for it, keeping unit economics intact.
- Cluster expansion keeps costs down - rather than spreading thin across the country, MedPlus deepens its presence in states where it already has warehouses and supply-chain infrastructure. Around 45% of stores sit in Tier-2 cities and beyond, where rents and staff costs are lower and the private-label mix is richer, so store-level EBITDA is actually better than in metros.
- A store pays for itself fast - each new outlet costs roughly ₹30 lakhs to set up and serves as its own customer-acquisition channel, avoiding the high marketing spend of online-only rivals. Stores older than 12 months delivered a store-level EBITDA margin of 13.1% and an operating return on capital employed of 80% in Q4 FY26, with inventory settling at 36 days once a store matures beyond its first year.
2. Diagnostics: subscription health plans sold through the same neighbourhood
A chain of pathology and radiology centres, still concentrated in Hyderabad, that sells health plans on a subscription model - customers pay a small premium and then get tests at a steep discount or free with a 25% co-pay.
- Built on pharmacy footfall - the diagnostics business was piloted in Hyderabad in March 2022, leveraging the trust and walk-in traffic that MedPlus’s pharmacy stores already generate in the city. It now operates four full-service diagnostic centres with MRI and CT, eight Level-2 centres, and over 100 collection centres, all within Hyderabad.
- Subscription, not transaction - the model is built around health plans rather than one-off tests. As of March 2026, the business had around 200,000 active plans, with daily gross plan sales running at over 550 per day. The observed on-time renewal rate was 21% in Q4 FY26, and the company is exploring B2B channels through insurance brokers and corporate OPD tie-ups to widen the subscriber base.
- Capex-heavy but now contributing - over ₹120 crores went into setting up the initial 12 diagnostic centres, making this a capital-intensive build-out. In FY26, the segment generated full-year revenue of ₹1,309.9 million and an operating EBITDA of ₹196.0 million, a 15.0% margin, showing the model is beginning to cover its costs.
Group structure and partners
A listed parent company with a backwards-integrated operating subsidiary, a recently amalgamated manufacturing arm, and an insurance broking licence held in reserve.
- MedPlus Health Services Limited is the listed entity on BSE and NSE, with its registered office in Hyderabad, Telangana. The operating engine for pharmacy retail appears to sit inside Optival Health Solutions Private Limited, a direct subsidiary where the Chief Retail Officer and Head of Supply Chain are designated.
- The group has consolidated its manufacturing capabilities through a Scheme of Amalgamation that merged MHS Pharmaceuticals Private Limited - a wholly-owned subsidiary engaged in manufacturing and distribution of pharmaceutical and FMCG products - into the parent company, effective April 2023 and approved by the NCLT in August 2024.
- MedPlus Insurance Brokers Private Limited was incorporated in July 2022 as a wholly-owned subsidiary with an authorised capital of ₹2 crores, holding a licence to carry on direct insurance broking in life and general insurance under IRDAI regulations, though it had not commenced operations at the time of incorporation.
- The board includes founder Dr Gangadi Madhukar Reddy as Chairman and Managing Director, alongside independent directors and, historically, nominee directors from Warburg Pincus and Prazim Trading and Investment Company Private Limited, reflecting private equity backing during the company’s growth phase.